CSF2 and atrial fibrillation: acAF and AF-EV treatment decreased extracellular GM-CSF levels by 80 ± 5% (p<0.01) and 98 ± 2% (p<0.001) respectively, IFNγ levels by 83 ± 11% (p<0.01) and 88 ± 5% (p<0.001), and IL-13 levels by 80 ± 7% (p<0.0001) and 92 ± 3% (p<0.0001).